Home > What we do > Medicine & Healthcare > hMedicine > hMedicine Story

BioLineRx to Commence Phase 1 Stem Cell Trial at Hadassah Medical Organization

BioLineRx Ltd. has received approval from the Israeli Ministry of Health to commence a Phase 1 trial for BL-8040, a novel treatment for mobilizing stem cells from the bone marrow for treating acute myeloid leukemia, as well as other hematological malignancies. The study is expected to begin during the third quarter of 2014 at the Hadassah Medical Organization.

Dr. Kinneret Savitsky, Chief Executive Officer of BioLineRx, explains that stem cell mobilization is being used more and more as a method of collecting stem cells, instead of the traditional surgical procedure of bone marrow harvesting. Current treatment regimens, she notes, involve daily injections of G-CSF, a growth factor that stimulates the bone marrow to make white blood cells.

These injections are given for 4-6 days with or without the addition of a mobilizing agent such as Plerixafor (Mozobil). A previous Phase 1/2 study in multiple myeloma patients revealed that BL-8040 given as a single injection in combination with G-CSF injections was highly effective in mobilizing stem cells. The current trial aims to evaluate the mobilization capacity of one or two injections of BL-8040 as a stand-alone therapy, which could significantly shorten treatment and reduce costs.

Date: 6/19/2014

Hadassah Stem Cell Expert Speaks at TEDx Conference in Jaffa

FDA Grants Approval for US Clinical Trials of Hadassah-Developed Technology to Treat Fatty Liver Disease

Hadassah Physicians Receive Prestigious Grants and Awards

New Research at Hadassah: Computational Tools Unravel the Mystery of Transient Amnesia

From Life-Threatening Brain Bleed to Birth of a Daughter

Cookbook Author, Rabbi Marks, Spends Last Days at Hadassah's Hospice

Hadassah’s Revolutionary Tipat Halav Clinics of 1920s Featured in Jerusalem Old City Museum

Victims of Terror Share Their Stories of Anguish and Appreciation with Hadassah President

Hadassah’s Advanced Gene Sequencing Changes the Life of a Family from Uzbekistan

IDF Medic Heroically Battles Terrorist, Both Treated at Hadassah

Orthopedic Trauma Turns Tragedy into Innovation at Hadassah

On the Cutting-Edge of Melanoma Treatment: Hadassah’s Protocols and Research

Saving a Newborn from a Life Without Sight

Terrorist and Victim Sent to Hadassah's Hospitals After Third Attack in Two Weeks

Three Sent to Hadassah After Second Jerusalem Terror Attack of the Week

Clinical Trial of Hadassah-Developed Stem Cell Treatment for Macular Degeneration Gets Go-Ahead from FDA

“We Don’t Say ‘No’,” Hadassah Neurosurgeon Explains in Operating on 82-Year-Old Patient

Cutting-Edge Medicine and Research; a Role Model for Peace: A Briefing from the Hospital's Director General

4 Ways Hadassah Hospital is Preparing for Ebola—Just in Case

Hailing from 17 Countries: the 39th Graduation Class of Hadassah’s International Master of Public Health Program



More hMedicine Stories




Hadasit, Hadassah’s Technology Transfer Arm, Reviews 2012’s Accomplishments

When the Hadassah University Medical Center’s physicians suggest a solution to a medical problem which can lead to the development of a new medicine or product, Hadasit, Hadassah’s technology transfer arm, explores its feasibility and supports the promotion of those viable ideas with innovation potential. Although 2012 has been “a year full of challenges for the life science industry,” says Einat Zisman, Hadasit’s Chief Executive Officer, Hadasit still signed 125 agreements for clinical trials, all to be done at Hadassah. In addition, Hadasit signed 15 agreements for cooperation and commercialization of technologies that were developed at Hadassah. Click here to read the latest Newsletter from Hadasit >>

   |  Who We Are  |  What We Do  |  Where We Do It  |  Read About It  |  Join Now  |  Donate  |
  |  Login  |  Contact Us  |  Careers  |  Terms & Conditions  |  
Copyright ©2014 Hadassah is a registered trademark of Hadassah, the Women's Zionist Organization of America